SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+metastatic breast cancer (MBC).

被引：7
|
作者：
Rugo, Hope S.
Pegram, Mark D.
Gradishar, William John
Cortes, Javier
Curigliano, Giuseppe
Wigginton, Jon M.
Lechleider, Robert Joseph
Cardoso, Fatima
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94132 USA
[2] Stanford Sch Med, Stanford, CA 94305 USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[4] Vall Hebron Inst Oncol, Barcelona, Spain
[5] Ist Europeo Oncol, Milan, Italy
[6] MacroGen Inc, Rockville, MD USA
[7] Champalimaud Canc Ctr, Lisbon, Portugal
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS630
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS630
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer
    Macpherson, Iain R.
    Spiliopoulou, Pavlina
    Rafii, Saeed
    Saggese, Matilde
    Baird, Richard D.
    Garcia-Corbacho, Javier
    Italiano, Antoine
    Bonneterre, Jacques
    Campone, Mario
    Cresti, Nicola
    Posner, John
    Takeda, Yousuke
    Arimura, Akinori
    Spicer, James
    BREAST CANCER RESEARCH, 2019, 22 (01)
  • [32] Whole exome sequencing (WES) in HER2+metastatic breast cancer (MBC) patients (pts) with extraordinary responses to trastuzumab (T)
    Luis, Ines Maria Vaz Duarte
    Oh, Coyin
    Wang, Zhigang
    Dipiro, Pamela
    Macrae, Erin Macrae
    Painter, Corrie
    Kryukov, Gregory
    Krop, Ian E.
    Winer, Eric P.
    Lin, Nancy U.
    Wagle, Nikhil
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer
    Iain R. Macpherson
    Pavlina Spiliopoulou
    Saeed Rafii
    Matilde Saggese
    Richard D. Baird
    Javier Garcia-Corbacho
    Antoine Italiano
    Jacques Bonneterre
    Mario Campone
    Nicola Cresti
    John Posner
    Yousuke Takeda
    Akinori Arimura
    James Spicer
    Breast Cancer Research, 22
  • [34] An Evaluation of the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2+Metastatic Breast Cancer
    Esteva, F. J.
    Franco, S. X.
    Hagan, M. K.
    Somer, R. A.
    Dombroski, C. S.
    Florance, A. M.
    Turner, S. J.
    Stein, S.
    Perez, A.
    CANCER RESEARCH, 2009, 69 (24) : 793S - 793S
  • [35] Phase II trial of gemcitabine plus carboplatin (plus trastuzumab in HER2+patients) in metastatic breast cancer patients
    Loesch, DM
    Asmar, L
    McIntyre, KJ
    Doane, LL
    McKittrick, RJ
    Monticelli, MA
    Paul, D
    Vukelja, SJ
    Zhan, F
    Boehm, KA
    O'Shaughnessy, J
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S280 - S281
  • [36] Effective anti-diarrhea strategies for pyrotinib (PYR) plus trastuzumab (H) and docetaxel (T) in patients ( pts) with HER2+metastatic breast cancer (mBC): a multicenter, phase 1 trial (PHAENNA)
    Yao, H.
    Shi, Y.
    Yao, Y.
    Li, H.
    Zhou, H.
    Wang, S.
    Qin, Q.
    Li, W.
    Geng, C.
    Wang, M.
    Wang, X.
    Cao, Y.
    Yu, Z.
    Du, C.
    Zhao, W.
    Wu, S.
    Cui, Y.
    Liu, P.
    Lin, J.
    Song, E.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 50 - 51
  • [37] Larotaxel (L) in combination with trastuzumab in patients with HER2+metastatic breast cancer (MBC): Interim analysis of an open phase II label study
    Dieras, V.
    Viens, P.
    Veyret, C.
    Romieu, G.
    Awada, A.
    Lidbrink, E.
    Bonnefoi, H.
    Mery-Mignard, D.
    Dalenc, F.
    Roche, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T plus AI vs L plus AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE.
    Gradishar, William John
    Hegg, Roberto
    Im, Seock-Ah
    Park, In Hae
    Tjulandin, Sergei
    Kenny, Sarah
    Sarp, Severine
    Williams, Lisa
    Izquierdo, Miguel A.
    Johnston, Stephen R. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Phase 1b/2 trial of the HER3 inhibitor patritumab (U3-1287) in combination with trastuzumab plus paclitaxel in newly-diagnosed patients with HER2+metastatic breast cancer (MBC)
    Carraro, S.
    Campos, D.
    Copigneaux, C.
    Saintilien, C.
    Beckman, R. A.
    Korbenfeld, E.
    Coppola, M. P.
    Halabe, K.
    Cazap, E.
    CANCER RESEARCH, 2013, 73
  • [40] Trastuzumab and vinorelbine or taxane chemotherapy for HER2+metastatic breast cancer: The TRAVIOTA study.
    Burstein, H. J.
    Keshaviah, A.
    Baron, A.
    Hart, R.
    Lambert-Falls, R.
    Marcom, P. K.
    Gelman, R.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 40S - 40S
12345